Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

BACKGROUND: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Raoul, Jean-Luc, Van Laethem, Jean-Luc, Peeters, Marc, Brezault, Catherine, Husseini, Fares, Cals, Laurent, Nippgen, Johannes, Loos, Anja-Helena, Rougier, Philippe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678147/
https://www.ncbi.nlm.nih.gov/pubmed/19366444
http://dx.doi.org/10.1186/1471-2407-9-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678147/
https://www.ncbi.nlm.nih.gov/pubmed/19366444
http://dx.doi.org/10.1186/1471-2407-9-112

Ejemplares similares